Siegfried Holding AG logo

Siegfried Holding AG (SFZNz)

Market Closed
CBOE CBOE
- Market Cap
24.55 P/E Ratio
0.43% Div Yield
- Volume
31.85 Eps
Want to track SFZNz and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SFZNz pays dividends to its shareholders, with the most recent payment made on Apr 30, 2026. The next estimated payment will be in In 10 months on Apr 30, 2027 for a total of 0.4 CHF.
The last earnings report, released on Feb 16, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -5.54%, based on the last three reports.
Siegfried Holding AG has completed 3 stock splits, with the recent split occurring on Apr 30, 2025.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on SIX (CHF).

Siegfried Holding AG (SFZNz) FAQ

On which exchange is it traded?

Siegfried Holding AG is listed on CBOE.

What is its stock symbol?

The ticker symbol is SFZNz.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.43%.

What is its market cap?

As of today, no market cap data is available.

Has Siegfried Holding AG ever had a stock split?

Siegfried Holding AG had 3 splits and the recent split was on Apr 30, 2025.

Siegfried Holding AG Profile

Specialty Retail Industry
Consumer Discretionary Sector
Ms. Jo-Anne O'Connor CEO
CBOE Exchange
CH0014284498 ISIN
CA Country
- Employees
24 Apr 2025 Last Dividend
28 Apr 2025 Last Split
- IPO Date

Overview

Siegfried Holding AG, founded in 1873 and headquartered in Zofingen, Switzerland, operates globally, providing a comprehensive range of services to the pharmaceutical industry. The company specializes in contract development and manufacturing, offering a wide array of solutions across active pharmaceutical ingredients (APIs) and finished dosage forms. It caters to various pharmaceutical needs through its subsidiaries, ensuring a seamless process from development to commercial manufacturing and packaging. Siegfried Holding AG stands as a vital partner to the pharmaceutical sector, leveraging its extensive experience and technological capabilities to deliver high-quality, innovative products and services.

Products and Services

  • Pharmaceutical and Analytical Development - Siegfried provides comprehensive development services, including pharmaceutical formulation and analytical development coupled with process and analytical transfer capabilities, ensuring products meet the highest quality standards.
  • Commercial Manufacturing and Packaging - The company offers large-scale manufacturing services for APIs and finished dosage forms, as well as packaging solutions that comply with global regulations, supporting products from concept to consumer.
  • Scale-up and Clinical Trial Material Production - Specializing in the production of materials for clinical trials, Siegfried facilitates the transition from small-scale development to commercial-scale manufacturing, ensuring the scalability of processes and products.
  • APIs and Intermediates Production - It develops and manufactures a wide range of high-quality APIs and intermediates, serving as the backbone for a vast number of pharmaceutical products.
  • Finished Dosage Forms - The company produces a variety of finished dosage forms, including solid oral, injectables (sterile and aseptic), ophthalmics, and inhalative products, catering to multiple therapeutic areas and delivery requirements.
  • APIs and Controlled Substances - Siegfried focuses on anesthetics, pain and addiction treatment, and treatments for central nervous and respiratory diseases, including caffeine for human health and nutrition.
  • Exclusive Synthesis Services - Offering specialized services in process and chemical development, analytical development, pilot manufacturing and scale-up, and commercial manufacturing, tailored to the specific needs of clients.
  • Viral Vector Manufacturing Solutions - The company provides cutting-edge solutions for the manufacturing of viral vectors, critical components in gene therapy and vaccine development.
  • Licensing, Registration Dossiers, and Common Technical Document Preparation - Siegfried assists with the licensing of oral solid and sterile products, assembles registration dossiers, and prepares common technical documents to facilitate market entry and compliance.

Contact Information

Address: 240 11 Avenue SW, Calgary, AB, Canada, T2R 0C3
Phone: 833-743-4743